{"disease":{"id":"endometrial-cancer","name":"Endometrial Cancer","therapeutic_area":"Oncology","data":{"aiSummary":"The treatment landscape for endometrial cancer includes surgery, radiation, chemotherapy, and hormonal therapy. Recent advances include the use of immunotherapy (pembrolizumab, dostarlimab) in MSI-H tumors and targeted therapies like lenvatinib. The pipeline includes several agents in clinical trials, including ADC and other targeted therapies, with the potential to improve outcomes in advanced or recurrent disease.","drug_count":6,"description":"Endometrial cancer is a malignancy that originates in the inner lining of the uterus (endometrium). The most common type is endometrioid adenocarcinoma. Risk factors include obesity, unopposed estrogen exposure, and a history of tamoxifen use. Treatment typically involves surgery, radiation, chemotherapy, and hormonal therapy.","subtype_count":10},"enrichment_level":2,"last_enriched_at":null,"visit_count":0,"created_at":"2026-03-25T12:16:34.924Z","updated_at":"2026-03-25T12:16:34.924Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":0,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"dostarlimab","indication_name":"Recurrent or advanced endometrial cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jemperli","generic_name":"DOSTARLIMAB","company_name":"GSK","drug_phase":"marketed","molecular_target":"PD-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":55,"revenue":"800","mechanism":"Dostarlimab-gxly binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, enhancing the immune response against tumors."},{"drug_id":"dostarlimab-gxly","indication_name":"Endometrial Cancer - Single Agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"JEMPERLI","generic_name":"DOSTARLIMAB-GXLY","company_name":"GLAXOSMITHKLINE","drug_phase":"marketed","molecular_target":"PD-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":49,"revenue":null,"mechanism":"Dostarlimab-gxly blocks PD-1 receptor interaction with PD-L1 and PD-L2, enhancing anti-tumor immune response."},{"drug_id":"chembl-chembl3301587","indication_name":"Advanced or Recurrent Endometrial Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DURVALUMAB","company_name":"","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":50,"revenue":null,"mechanism":"Durvalumab binds to PD-L1, blocking its interaction with PD-1 and CD80, enhancing T-cell activation and reducing tumor size."},{"drug_id":"dostarlimab-gxly","indication_name":"Endometrial Cancer - Combination Therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"JEMPERLI","generic_name":"DOSTARLIMAB-GXLY","company_name":"GLAXOSMITHKLINE","drug_phase":"marketed","molecular_target":"PD-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":49,"revenue":null,"mechanism":"Dostarlimab-gxly blocks PD-1 receptor interaction with PD-L1 and PD-L2, enhancing anti-tumor immune response."},{"drug_id":"dostarlimab-gxly","indication_name":"Recurrent or advanced endometrial cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"JEMPERLI","generic_name":"DOSTARLIMAB-GXLY","company_name":"GLAXOSMITHKLINE","drug_phase":"marketed","molecular_target":"PD-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":49,"revenue":null,"mechanism":"Dostarlimab-gxly blocks PD-1 receptor interaction with PD-L1 and PD-L2, enhancing anti-tumor immune response."},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of endometrial cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic endometrial cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":7,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01267851","title":"Clinical Database and Biobank of Patients With Gynecologic Neoplasms","phase":"","overall_status":"UNKNOWN","enrollment_count":1600000,"lead_sponsor_name":"Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT05506800","title":"Guangzhou Women's Health Cohort Study (GWHCS)","phase":"","overall_status":"SUSPENDED","enrollment_count":1000000,"lead_sponsor_name":"Guangzhou Women and Children's Medical Center","has_results":false},{"nct_id":"NCT04334239","title":"Effectiveness of Care in Certified Cancer Centres in Germany","phase":"","overall_status":"COMPLETED","enrollment_count":670000,"lead_sponsor_name":"Technische Universität Dresden","has_results":false},{"nct_id":"NCT03285230","title":"The French E3N Prospective Cohort Study","phase":"","overall_status":"UNKNOWN","enrollment_count":100000,"lead_sponsor_name":"Institut National de la Santé Et de la Recherche Médicale, France","has_results":false},{"nct_id":"NCT05142033","title":"Avera Cancer Sequencing and Analytics Protocol (ASAP)","phase":"","overall_status":"RECRUITING","enrollment_count":25000,"lead_sponsor_name":"Avera McKennan Hospital & University Health Center","has_results":false},{"nct_id":"NCT00340262","title":"Bone Mineral Density and Subsequent Cancer Risk","phase":"","overall_status":"COMPLETED","enrollment_count":15595,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05912972","title":"Development and Management of Registry in Patients With Gynecologic Cancer in Korea","phase":"","overall_status":"RECRUITING","enrollment_count":13500,"lead_sponsor_name":"Asan Medical Center","has_results":false},{"nct_id":"NCT00342446","title":"A Follow-up Study of Women Evaluated and Treated for Infertility","phase":"","overall_status":"COMPLETED","enrollment_count":12193,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00340600","title":"Continuation of Follow-up of DES-Exposed Cohorts","phase":"","overall_status":"COMPLETED","enrollment_count":10805,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05290415","title":"Host DNA Methylation for Endometrial Cancer Screening","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT04096872","title":"Clinical Application of Laparo-endoscopic Single-site Surgery and Natural Orifice Transluminal Endoscopic in Gynecology","phase":"","overall_status":"UNKNOWN","enrollment_count":9000,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT05290922","title":"DNA CDO1 and CELF4 Methylation for Endometrial Cancer Screening","phase":"","overall_status":"UNKNOWN","enrollment_count":7150,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT00340210","title":"Extended Follow-up of Columbia, MO Serum Bank Participants","phase":"","overall_status":"COMPLETED","enrollment_count":6720,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05635123","title":"A Cohort Study of Uterine Malignancies","phase":"","overall_status":"RECRUITING","enrollment_count":6200,"lead_sponsor_name":"Women's Hospital School Of Medicine Zhejiang University","has_results":false},{"nct_id":"NCT00340808","title":"Molecular Staging of Endometrial Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":5492,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06440018","title":"INSPIRE: a Multi-Cancer Early Detection Study","phase":"","overall_status":"RECRUITING","enrollment_count":5350,"lead_sponsor_name":"Singlera Genomics Inc.","has_results":false},{"nct_id":"NCT05051722","title":"Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":3110,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT07148154","title":"Development of a Non-invasive IVD for Endometrial Cancer Screening on High-risk Populations","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"MiMARK Diagnostics, S.L.","has_results":false},{"nct_id":"NCT05697601","title":"Predictors of Ovarian Cancer and Endometrial Cancer for Artificial-Intelligence-Based Screening Tools","phase":"","overall_status":"UNKNOWN","enrollment_count":2905,"lead_sponsor_name":"Hasanuddin University","has_results":false},{"nct_id":"NCT05387460","title":"Radiomics Based Multimodal Transvaginal Ultrasound Imaging in Endometrial Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT01793545","title":"Endometrial Cancer Testing With Vaginal and Endometrial Cell Samples","phase":"","overall_status":"COMPLETED","enrollment_count":1932,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06935305","title":"OSNA Versus Ultrastaging to Detect Sentinel Lymph Node Metastasis in Endometrial Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":1922,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT06284343","title":"The Gynecological Cancer Associated Thrombosis (GynCAT) Study","phase":"","overall_status":"RECRUITING","enrollment_count":1800,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT04291612","title":"Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease","phase":"","overall_status":"RECRUITING","enrollment_count":1715,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT05255653","title":"Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":1615,"lead_sponsor_name":"Leiden University Medical Center","has_results":false},{"nct_id":"NCT02628067","title":"Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1609,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT03538665","title":"The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":false},{"nct_id":"NCT00587886","title":"Estrogen, Diet, Genetics and Endometrial Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1315,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT05242276","title":"Uterine Manipulator in Endometrial Cancer Surgery: Pro MUCEI Study","phase":"","overall_status":"UNKNOWN","enrollment_count":1200,"lead_sponsor_name":"Instituto de Investigacion Sanitaria La Fe","has_results":false},{"nct_id":"NCT06952504","title":"A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1123,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT06096688","title":"Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction","phase":"","overall_status":"RECRUITING","enrollment_count":1120,"lead_sponsor_name":"Weill Medical College of Cornell University","has_results":false},{"nct_id":"NCT05707312","title":"Staging Endometrial caNcer Based on molEcular ClAssification","phase":"","overall_status":"UNKNOWN","enrollment_count":1032,"lead_sponsor_name":"Clinica Universidad de Navarra, Universidad de Navarra","has_results":false},{"nct_id":"NCT05056077","title":"Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)","phase":"NA","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT06977594","title":"Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT06279832","title":"Radiomics and Radiogenomics Models to Predict Molecular Integrated Risk Classes and Prognostic Factors in Endometrial Cancer.","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT06354738","title":"Improving Endometrial Cancer Assessment by Combining Genomic Profiling and Surgical Assessment","phase":"NA","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University Hospital, Gasthuisberg","has_results":false},{"nct_id":"NCT04917341","title":"The Compatibility of Preoperative Endometrial Biopsies With Postoperative Final Pathology in Endometrial Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":960,"lead_sponsor_name":"Batman Training and Research Hospital","has_results":false},{"nct_id":"NCT03170960","title":"Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":914,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT03564340","title":"Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":890,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT05162846","title":"Michigan Genetic Hereditary Testing (MiGHT)","phase":"NA","overall_status":"COMPLETED","enrollment_count":831,"lead_sponsor_name":"University of Michigan Rogel Cancer Center","has_results":false},{"nct_id":"NCT05717634","title":"Endometrial Changes in Breast Cancer Women.","phase":"","overall_status":"UNKNOWN","enrollment_count":829,"lead_sponsor_name":"Regina Elena Cancer Institute","has_results":false},{"nct_id":"NCT04845828","title":"Randomized Comparison Between Sentinel Lymph Node Biopsy and Lymph Node Dissection in Early Stage Endometrial Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":810,"lead_sponsor_name":"Asan Medical Center","has_results":false},{"nct_id":"NCT06028724","title":"A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)","phase":"","overall_status":"RECRUITING","enrollment_count":782,"lead_sponsor_name":"Centro di Riferimento Oncologico - Aviano","has_results":false},{"nct_id":"NCT04276532","title":"Sentinel Lymph Node Sampling for Patients With Middle-high Risk Endometrial Cancer Confined to the Uterus","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":780,"lead_sponsor_name":"Xiaojun Chen","has_results":false},{"nct_id":"NCT04122235","title":"The Lifestyle and Empowerment Techniques in Survivorship of Gynecologic Oncology Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":755,"lead_sponsor_name":"Sorlandet Hospital HF","has_results":false},{"nct_id":"NCT00339651","title":"Preliminary Study of Endometrial Hyperplasia Groundwork for a Study to Define Precursors of Endometrial Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":745,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06172478","title":"A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":740,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT07200466","title":"Individualised Endometrial Cancer Risk Stratification by Bayesian Prediction Model (ENDORISK), Optimizing Clinical Implementation","phase":"NA","overall_status":"RECRUITING","enrollment_count":735,"lead_sponsor_name":"Radboud University Medical Center","has_results":false},{"nct_id":"NCT05208762","title":"A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":714,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT06132958","title":"Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":710,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}